2025 North America Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report
Description
The 2025 North America Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American cancer immunotherapy drug discovery outsourcing market include Covance, Inc., Personalis, Inc., STC Biologics, and Molecular Imaging, Inc. Covance, Inc. is a leading Contract Research Organization (CRO) with strong capabilities in oncology drug discovery and development services. Personalis, Inc. is notable for its advanced genomic sequencing platforms, enabling personalized cancer vaccine development in collaboration with key biotech companies. STC Biologics specializes in immuno-oncology-focused bioanalytical services supporting drug discovery pipelines. Molecular Imaging, Inc. provides innovative imaging solutions critical for preclinical cancer immunotherapy research.
These companies benefit from North America’s well-established healthcare infrastructure, skilled workforce, and regulatory expertise, which contribute to the region's dominance in this market with over 36% share. The U.S. leads growth due to its concentration of pharmaceutical and biotechnology firms, cutting-edge technology adoption such as next-generation sequencing and AI, and strategic partnerships facilitating faster oncology drug discovery. Increasing cancer prevalence and investment in immunotherapies further propel demand for outsourcing, as these firms offer specialized expertise that accelerates development timelines and reduces costs for pharma partners.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Immunotherapy Drug Discovery Outsourcing Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North American cancer immunotherapy drug discovery outsourcing market include Covance, Inc., Personalis, Inc., STC Biologics, and Molecular Imaging, Inc. Covance, Inc. is a leading Contract Research Organization (CRO) with strong capabilities in oncology drug discovery and development services. Personalis, Inc. is notable for its advanced genomic sequencing platforms, enabling personalized cancer vaccine development in collaboration with key biotech companies. STC Biologics specializes in immuno-oncology-focused bioanalytical services supporting drug discovery pipelines. Molecular Imaging, Inc. provides innovative imaging solutions critical for preclinical cancer immunotherapy research.
These companies benefit from North America’s well-established healthcare infrastructure, skilled workforce, and regulatory expertise, which contribute to the region's dominance in this market with over 36% share. The U.S. leads growth due to its concentration of pharmaceutical and biotechnology firms, cutting-edge technology adoption such as next-generation sequencing and AI, and strategic partnerships facilitating faster oncology drug discovery. Increasing cancer prevalence and investment in immunotherapies further propel demand for outsourcing, as these firms offer specialized expertise that accelerates development timelines and reduces costs for pharma partners.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
